Prothena Co. PLC (NASDAQ:PRTA) – Equities research analysts at Wedbush raised their Q1 2018 earnings per share (EPS) estimates for Prothena in a report issued on Wednesday. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will earn ($0.83) per share for the quarter, up from their previous forecast of ($1.50). Wedbush also issued estimates for Prothena’s Q2 2018 earnings at ($0.83) EPS, Q3 2018 earnings at ($0.73) EPS, Q4 2018 earnings at ($0.50) EPS, FY2018 earnings at ($2.87) EPS, FY2019 earnings at ($1.81) EPS, FY2020 earnings at ($2.07) EPS, FY2021 earnings at ($3.47) EPS and FY2022 earnings at ($0.98) EPS.
Several other analysts also recently issued reports on the company. BidaskClub raised Prothena from a “sell” rating to a “hold” rating in a report on Friday. Deutsche Bank reissued a “buy” rating on shares of Prothena in a report on Wednesday, March 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $69.00 price target on shares of Prothena in a report on Wednesday, March 21st. Oppenheimer set a $70.00 price target on Prothena and gave the stock a “buy” rating in a report on Wednesday, March 21st. Finally, Zacks Investment Research raised Prothena from a “sell” rating to a “hold” rating in a report on Monday, February 19th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the stock. Prothena currently has a consensus rating of “Buy” and an average price target of $74.91.
Prothena (NASDAQ:PRTA) last released its earnings results on Wednesday, February 14th. The biotechnology company reported ($1.24) EPS for the quarter, topping analysts’ consensus estimates of ($1.48) by $0.24. The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.27 million. Prothena had a negative return on equity of 33.37% and a negative net margin of 556.84%. Prothena’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same quarter last year, the business posted ($1.41) EPS.
A number of institutional investors have recently made changes to their positions in PRTA. Fieldpoint Private Securities LLC bought a new stake in Prothena during the 3rd quarter valued at $162,000. Teacher Retirement System of Texas bought a new stake in Prothena during the 3rd quarter valued at $206,000. First Trust Advisors LP bought a new stake in Prothena during the 3rd quarter valued at $212,000. HBK Investments L P bought a new stake in Prothena during the 4th quarter valued at $213,000. Finally, Jefferies Group LLC bought a new stake in Prothena during the 4th quarter valued at $292,000.
COPYRIGHT VIOLATION NOTICE: “Q1 2018 Earnings Forecast for Prothena Co. PLC (PRTA) Issued By Wedbush” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3300637/q1-2018-earnings-forecast-for-prothena-co-plc-prta-issued-by-wedbush.html.
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.